Junko Murai

8.3k total citations · 3 hit papers
76 papers, 6.0k citations indexed

About

Junko Murai is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Junko Murai has authored 76 papers receiving a total of 6.0k indexed citations (citations by other indexed papers that have themselves been cited), including 55 papers in Molecular Biology, 47 papers in Oncology and 7 papers in Cancer Research. Recurrent topics in Junko Murai's work include PARP inhibition in cancer therapy (37 papers), DNA Repair Mechanisms (31 papers) and Cancer therapeutics and mechanisms (20 papers). Junko Murai is often cited by papers focused on PARP inhibition in cancer therapy (37 papers), DNA Repair Mechanisms (31 papers) and Cancer therapeutics and mechanisms (20 papers). Junko Murai collaborates with scholars based in Japan, United States and United Kingdom. Junko Murai's co-authors include Yves Pommier, Shunichi Takeda, James H. Doroshow, Yiping Zhang, Jiuping Ji, Benu Brata Das, Amèlie Renaud, Shar-yin N. Huang, Shar-yin N. Huang and Joel Morris and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nucleic Acids Research and Journal of Biological Chemistry.

In The Last Decade

Junko Murai

74 papers receiving 5.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors

2012 1.6k citations Junko Murai, Shar-yin N. Huang et al. Cancer Research profile →
Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib

2013 592 citations Junko Murai, Shar-yin N. Huang et al. Molecular Cancer Therapeutics profile →
A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress

2017 379 citations Junko Murai, Yves Pommier et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Junko Murai Japan	35	4.5k	4.2k	486	471	467	76	6.0k
János L. Tanyi United States	36	1.9k 0.4×	1.7k 0.4×	96 0.2×	301 0.6×	720 1.5×	113	3.9k
Christina M. Annunziata United States	37	2.5k 0.6×	2.6k 0.6×	63 0.1×	457 1.0×	1.0k 2.2×	155	5.4k
Alison L. Hannah United States	31	2.5k 0.6×	2.5k 0.6×	69 0.1×	665 1.4×	763 1.6×	122	4.9k
Jasgit C. Sachdev United States	23	1.7k 0.4×	1.6k 0.4×	63 0.1×	197 0.4×	947 2.0×	126	3.4k
Toshiyasu Taniguchi United States	44	7.9k 1.8×	3.5k 0.8×	96 0.2×	2.1k 4.5×	2.8k 6.0×	83	9.8k
Rena G. Lapidus United States	31	3.4k 0.8×	1.6k 0.4×	38 0.1×	615 1.3×	749 1.6×	99	4.9k
Jennifer L. Hsu United States	29	2.7k 0.6×	2.4k 0.6×	47 0.1×	180 0.4×	1.3k 2.8×	62	5.1k
Xi Zhang China	32	1.8k 0.4×	1.8k 0.4×	99 0.2×	507 1.1×	462 1.0×	274	4.6k
Paul A. Beavis Australia	36	2.2k 0.5×	4.1k 1.0×	241 0.5×	591 1.3×	541 1.2×	62	6.6k
Wei‐Zhong Wu China	41	3.5k 0.8×	2.1k 0.5×	70 0.1×	157 0.3×	1.9k 4.0×	107	5.7k

Countries citing papers authored by Junko Murai

Since Specialization

Citations

This map shows the geographic impact of Junko Murai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Junko Murai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Junko Murai more than expected).

Fields of papers citing papers by Junko Murai

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Junko Murai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Junko Murai. The network helps show where Junko Murai may publish in the future.

Co-authorship network of co-authors of Junko Murai

This figure shows the co-authorship network connecting the top 25 collaborators of Junko Murai. A scholar is included among the top collaborators of Junko Murai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Junko Murai. Junko Murai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Natsumeda, Manabu, Akihide Koyama, Jun Watanabe, et al.. (2025). Diagnosis of Leptomeningeal Disease in Diffuse Midline Gliomas by Detection of H3F3A K27M Mutation in Circulating Tumor DNA of Cerebrospinal Fluid. Pediatric Blood & Cancer. 72(4). e31535–e31535. 1 indexed citations

Sakaue, Tomohisa, Miho Kawaida, Nobuyuki Onishi, et al.. (2024). Schlafen 11 further sensitizes BRCA-deficient cells to PARP inhibitors through single-strand DNA gap accumulation behind replication forks. Oncogene. 43(32). 2475–2489. 8 indexed citations

Murai, Junko, Michele Ceribelli, Haiqing Fu, et al.. (2023). Schlafen 11 (SLFN11) Kills Cancer Cells Undergoing Unscheduled Re-replication. Molecular Cancer Therapeutics. 22(8). 985–995. 5 indexed citations

Yachida, Nozomi, Manako Yamaguchi, Kaoru Yamawaki, et al.. (2023). SLFN11 is a BRCA Independent Biomarker for the Response to Platinum-Based Chemotherapy in High-Grade Serous Ovarian Cancer and Clear Cell Ovarian Carcinoma. Molecular Cancer Therapeutics. 23(1). 106–116. 8 indexed citations

Murai, Yasuhisa, Ukhyun Jo, Junko Murai, et al.. (2021). SLFN11 Inactivation Induces Proteotoxic Stress and Sensitizes Cancer Cells to Ubiquitin Activating Enzyme Inhibitor TAK-243. Cancer Research. 81(11). 3067–3078. 33 indexed citations

Takashima, Tsuyoshi, Daiki Taniyama, Naoya Sakamoto, et al.. (2021). Schlafen 11 predicts response to platinum-based chemotherapy in gastric cancers. British Journal of Cancer. 125(1). 65–77. 37 indexed citations

Taniyama, Daiki, Naoya Sakamoto, Tsuyoshi Takashima, et al.. (2021). Prognostic impact of Schlafen 11 in bladder cancer patients treated with platinum‐based chemotherapy. Cancer Science. 113(2). 784–795. 23 indexed citations

Pongor, Lőrinc Sándor, Roberto Vera Alvarez, Junko Murai, et al.. (2020). BAMscale: quantification of next-generation sequencing peaks and generation of scaled coverage tracks. Epigenetics & Chromatin. 13(1). 21–21. 38 indexed citations

Marzi, Laetitia, Ludmila Szabova, Zoë Weaver Ohler, et al.. (2019). The Indenoisoquinoline TOP1 Inhibitors Selectively Target Homologous Recombination-Deficient and Schlafen 11-Positive Cancer Cells and Synergize with Olaparib. Clinical Cancer Research. 25(20). 6206–6216. 43 indexed citations

10.

Khanal, Manakamana, Junko Murai, Qun Jiang, et al.. (2019). MA12.03 PARP Inhibitor Sensitivity Does Not Depend on BAP1 but Is Enhanced by Temozolomide in MGMT Deficient Human Mesothelioma Cells. Journal of Thoracic Oncology. 14(10). S296–S296. 1 indexed citations

11.

Marzi, Laetitia, Keli Agama, Junko Murai, et al.. (2018). Novel Fluoroindenoisoquinoline Non-Camptothecin Topoisomerase I Inhibitors. Molecular Cancer Therapeutics. 17(8). 1694–1704. 32 indexed citations

12.

Tang, Sai-Wen, Anish Thomas, Junko Murai, et al.. (2018). Overcoming Resistance to DNA-Targeted Agents by Epigenetic Activation of Schlafen 11 ( SLFN11) Expression with Class I Histone Deacetylase Inhibitors. Clinical Cancer Research. 24(8). 1944–1953. 65 indexed citations

13.

Murai, Junko. (2017). Targeting DNA repair and replication stress in the treatment of ovarian cancer. International Journal of Clinical Oncology. 22(4). 619–628. 54 indexed citations

14.

Bilke, Sven, Liang Cao, Junko Murai, et al.. (2015). SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma. Clinical Cancer Research. 21(18). 4184–4193. 70 indexed citations

15.

Marchand, Christophe, Shar-yin N. Huang, Thomas S. Dexheimer, et al.. (2014). Biochemical Assays for the Discovery of TDP1 Inhibitors. Molecular Cancer Therapeutics. 13(8). 2116–2126. 17 indexed citations

16.

Pommier, Yves, Shar-yin N. Huang, Rui Gao, et al.. (2014). Tyrosyl-DNA-phosphodiesterases (TDP1 and TDP2). DNA repair. 19. 114–129. 262 indexed citations

17.

Shimizu, Hiroyasu, Toru Fukushima, Toshiaki Kogame, et al.. (2013). Differential and Common DNA Repair Pathways for Topoisomerase I- and II-Targeted Drugs in a Genetic DT40 Repair Cell Screen Panel. Molecular Cancer Therapeutics. 13(1). 214–220. 106 indexed citations

18.

Murai, Junko, Shar-yin N. Huang, Amèlie Renaud, et al.. (2013). Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib. Molecular Cancer Therapeutics. 13(2). 433–443. 592 indexed citations breakdown →

19.

Murai, Junko, Shar-yin N. Huang, Benu Brata Das, et al.. (2012). Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. Cancer Research. 72(21). 5588–5599. 1613 indexed citations breakdown →

20.

Muranaka, Yoshinori, et al.. (2010). Asymmetric inhibition of spicule formation in sea urchin embryos with low concentrations of gadolinium ion. Development Growth & Differentiation. 52(9). 735–746. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact